Warfarin Sensitivity Test Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The warfarin sensitivity test market is expected to register a healthy CAGR during the forecast period. The major contributing factors responsible for driving the market growth are the increasing burden of blood-related disorders and technological advancements in the field.
Key HighlightsNorth America is expected to hold a major market share in the global warfarin sensitivity test market due to the rise in the aging population and the associated bleeding disorders. The geriatric population is at a higher risk of warfarin sensitivity. The elder population has decreased metabolic activities, which alter the pharmacokinetics of the drug, and hence, higher sensitivity is observed in the geriatric population. According to the data published by the US Census Bureau, in 2018, there were around 52 million people living at the age of 65 and above. Furthermore, according to the Center for Disease Control and Prevention, at least 900,000 people are likely to suffer from venous thromboembolism. Hence, these factors are expected to propel the warfarin sensitivity test market growth.
Competitive LandscapeThe companies have been constantly focused on developing new products related to warfarin sensitivity test, in order to grow their presence in the market. For instance, in 2019, Eurolyser DIagnostica Gmbh added bidirectional connectivity to the “CUBE” series to enhance the data management software. Some of the companies, which are currently dominating the market, are AutoGenomics, Abbott, Eurolyser Diagnostica GmbH, TrimGen Corporation, Generi Biotech, F. Hoffmann-La Roche Ltd, Acon Laboratories Inc., and Coagu Sense Inc.
Additional Benefits:Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook